JP2018516244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516244A5 JP2018516244A5 JP2017554475A JP2017554475A JP2018516244A5 JP 2018516244 A5 JP2018516244 A5 JP 2018516244A5 JP 2017554475 A JP2017554475 A JP 2017554475A JP 2017554475 A JP2017554475 A JP 2017554475A JP 2018516244 A5 JP2018516244 A5 JP 2018516244A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- fra
- composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149184P | 2015-04-17 | 2015-04-17 | |
| US62/149,184 | 2015-04-17 | ||
| PCT/US2016/027497 WO2016168440A1 (en) | 2015-04-17 | 2016-04-14 | Methods for treating lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516244A JP2018516244A (ja) | 2018-06-21 |
| JP2018516244A5 true JP2018516244A5 (enExample) | 2019-03-28 |
Family
ID=55809240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554475A Pending JP2018516244A (ja) | 2015-04-17 | 2016-04-14 | 肺がんを処置するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180125970A1 (enExample) |
| EP (1) | EP3283886B1 (enExample) |
| JP (1) | JP2018516244A (enExample) |
| KR (1) | KR20170137848A (enExample) |
| CN (1) | CN107624071A (enExample) |
| AU (1) | AU2016248222A1 (enExample) |
| BR (1) | BR112017022320A2 (enExample) |
| CA (1) | CA2983126A1 (enExample) |
| IL (1) | IL255079A0 (enExample) |
| MX (1) | MX2017013390A (enExample) |
| RU (1) | RU2718780C9 (enExample) |
| SG (1) | SG11201708546UA (enExample) |
| WO (1) | WO2016168440A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006241099B2 (en) * | 2005-04-22 | 2012-04-19 | Eisai, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| WO2015186823A1 (ja) * | 2014-06-06 | 2015-12-10 | 協和発酵キリン株式会社 | Ｆｏｌｒ１標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬 |
| US10822410B2 (en) | 2016-11-23 | 2020-11-03 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| CN115925952A (zh) | 2018-03-13 | 2023-04-07 | 东莞凡恩世生物医药有限公司 | 抗叶酸受体1抗体及其用途 |
| SG11202012576QA (en) * | 2018-06-18 | 2021-01-28 | Medimmune Ltd | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
| CN110221052B (zh) * | 2019-06-17 | 2022-09-23 | 昆山德诺瑞尔生物科技有限公司 | Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用 |
| EP4490517A1 (en) * | 2022-03-11 | 2025-01-15 | Astrazeneca AB | A scoring method for an anti-fr alpha antibody-drug conjugate therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005214331B2 (en) | 2004-02-12 | 2011-09-15 | Eisai, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| AU2006241099B2 (en) * | 2005-04-22 | 2012-04-19 | Eisai, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| WO2012061759A2 (en) | 2010-11-05 | 2012-05-10 | Morphotek Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| CN107011439B (zh) * | 2011-07-15 | 2020-11-10 | 卫材R&D管理有限公司 | 抗叶酸受体α抗体及其应用 |
-
2016
- 2016-04-14 RU RU2017136863A patent/RU2718780C9/ru not_active IP Right Cessation
- 2016-04-14 CA CA2983126A patent/CA2983126A1/en not_active Abandoned
- 2016-04-14 SG SG11201708546UA patent/SG11201708546UA/en unknown
- 2016-04-14 EP EP16718820.0A patent/EP3283886B1/en active Active
- 2016-04-14 JP JP2017554475A patent/JP2018516244A/ja active Pending
- 2016-04-14 US US15/566,888 patent/US20180125970A1/en not_active Abandoned
- 2016-04-14 MX MX2017013390A patent/MX2017013390A/es unknown
- 2016-04-14 WO PCT/US2016/027497 patent/WO2016168440A1/en not_active Ceased
- 2016-04-14 BR BR112017022320-1A patent/BR112017022320A2/en not_active Application Discontinuation
- 2016-04-14 KR KR1020177032864A patent/KR20170137848A/ko not_active Withdrawn
- 2016-04-14 AU AU2016248222A patent/AU2016248222A1/en not_active Abandoned
- 2016-04-14 CN CN201680028727.8A patent/CN107624071A/zh active Pending
-
2017
- 2017-10-17 IL IL255079A patent/IL255079A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516244A5 (enExample) | ||
| JP7325463B2 (ja) | がんの予後診断及び治療のための方法及び組成物 | |
| US20250154257A1 (en) | Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody | |
| US20220315657A1 (en) | Anti-pd-1 antibody for use in a method of treating a tumor | |
| AU2014312079B2 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
| RU2017136863A (ru) | Способы лечения рака легкого | |
| JP2016539083A5 (enExample) | ||
| KR20130055647A (ko) | 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법 | |
| TWI819011B (zh) | 以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法 | |
| US12183434B2 (en) | Diagnostic and therapeutic methods for cancer | |
| WO2016011052A1 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
| CA3119584A1 (en) | Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome | |
| WO2025080769A1 (en) | Methods of treating cancer | |
| WO2014205342A4 (en) | Methods for treatment of ovarian cancer | |
| JP2016529484A5 (enExample) | ||
| JP6312660B2 (ja) | Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法 | |
| Wang et al. | P-252 Real-world data: Different administration strategies of fruquintinib for metastatic colorectal cancer | |
| JPWO2022043538A5 (enExample) | ||
| Wang | Overcoming resistance of targeted EGFR/panHER monotherapy by inhibition of STAT3 escape pathway in sarcoma | |
| Kataoka et al. | Survival Outcome in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Followed by Cetuximab | |
| HK1230250A1 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
| HK1244302A1 (en) | Methods and compositions for prognosis and treatment of cancers |